FDA Ignores Tobacco Harm Reduction As Therapeutic Option – Experts
This article was originally published in The Tan Sheet
Executive Summary
FDA's tobacco product policies impede development of alternatives to smoking-cessation products with utility for harm reduction, according to an expert panel.
You may also be interested in...
New Products In Brief
Pfizer launches new line, extends Centrum
Advisory Committee On NRT Indications Appears Likely Following Workshop
Speakers at a workshop on nicotine-replacement therapy point abroad for guidance on expanding indications for smoking-cessation products as an FDA official says the agency likely will put the question before an advisory committee.
FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication